News for Vir Biotechnology, Inc. (VIR)

Vir Biotechnology Inc (VIR), a clinical-stage biopharmaceutical company, has announced that it will provide a corporate update and report its financial results

This is our list of the best health care stocks based on the highest return over the last 30 days.

**media[527277,527278]**

We recently compiled a list of the Why These 15 Stocks Are Skyrocketing in 2025. In this article, we are going to take a look at where Vir Biotechnology, Inc.

Alnylam Announces Preliminary* Fourth Quarter and Full Year 2024 Global Net Product Revenues and Provides 2025 Combined Net Product Revenue Guidance and Pipeline Goals

Vir Biotechnology (VIR) stock was upgraded by Morgan Stanley after the company posted trial data for two antitumor agents developed with Sanofi (SNY). Read more here.

On January 8, 2025, Vicki Sato, a Director at Vir Biotechnology Inc (VIR), sold 10,960 shares of the company, as reported in the SEC Filing. Following this tran

Vir Biotechnology's recent share price rally is driven by their promising cancer program. Having shot to over a $1.5B market cap, see if VIR stock is a Buy now.

U.S. stocks were lower, with the Dow Jones index falling over 150 points on Wednesday. Shares of AAR Corp. AIR rose sharply during Tuesday's session after post...

Seattle-based biotechnology company Sana Biotechnology, Inc. (SANA) is up over 227 percent in Wednesday's pre-market trading. The following are some of the other stocks making big moves in Wednesday's pre-market trading.

Vir Biotechnology, Inc. (VIR) Wednesday announced encouraging results from Phase 1 studies of its two drug candidates VIR-5818 and VIR-5500 in heavily pretreated patients with various solid tumors.

Vir Biotechnology stock soars on promising trial data

Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that tobevibart and elebsiran have received U.S. Food and Drug Administration (FDA) Breakthrough Therapy

North Carolina-based Cheetah Net Supply Chain Service Inc. (CTNT) is up over 267 percent in Tuesday's pre-market trading. The following are some of the other stocks making big moves in Tuesday's pre-market trading.

Shares of Credo Technology Group Holding Ltd CRDO rose sharply in today's pre-market trading after the company reported better-than-expected second-quarter fina...

- Building Team to Prepare for Commercialization as Company Pursues Expedited Approval Pathways for DM1 and DMD Clinical Programs - WALTHAM, Mass., Sept. ...

Quince’s transformation is complete with the acquisition of EryDel in October 2023. Check out the reasons why I rate QNCX stock as a Strong Buy.

The current therapeutic landscape of bacterial vaginosis is driven by approved therapies such as XACIATO, SOLOSEC, and VivaGel. The launch of novel...

Brii Biosciences Announces Two Breakthrough Therapy Designations for BRII-877 and BRII-835 Building on Extensive Clinical Evidence from Multiple Phase 2 Studies